RE-IMAGINE
MENTAL HEALTHCARE
Transforming evidence-based innovation into accessible mental health treatment to help change lives.
GrayMatters Health is leading a transformation by empowering mental healthcare professionals with an evidence-based technology that augments standard-of-care therapies to help improve patient outcomes and patient lives. This innovation is based on the world’s first digital biomarker of brain activity associated with mental health disorders.
​
Prism for PTSD is the first self-neuromodulation device to receive FDA clearance as a prescribed adjunct treatment for post-traumatic stress disorder (PTSD). Prism uses the amygdala-based biomarker to help patients learn to regulate brain activity associated with PTSD symptoms,
PRISM EMPOWERS
FDA-CLEARED.
As adjunctive treatment of symptoms associated with PTSD, to be used under the direction of a healthcare professional.
SCIENCE-BASEDâ€.‬
Prism’s amygdala-based biomarker technology
has been extensively researched.
IT WORKS.
In clinical trials, 67% of patients overall showed clinically significant symptom improvement three months after completing treatment.
FITS YOUR CLINIC.
Installation and training in the morning and treat patients that same afternoon. Can be operated by a non-MD.
IT IS SAFE.
Mild side effects, such as headache and fatigue self-resolved post treatment.
PATIENTS LIKE ITâ€.‬
Prism does not re-expose patients to trauma and studies have shown
10% attrition.